ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-HER2 Bispecific Antibody TQB2930

Also written as “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection”, “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)” and “TQB2930 injection+TQB2102 for injection”.

In Sino Biopharmaceutical’s pipeline, HER2双抗. Its studies are mostly in Breast Neoplasms · Colorectal Neoplasms, led by Sino Biopharmaceutical.

Drug pageAnti-HER2 Bispecific Antibody TQB2930: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Jun 24, 20255 company-led studies, 4 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical54 open or runningphase 3since Jun 24, 2025May 6, 2022Dec 2026phase 2 · NCT06202261

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 6, 2022First study: phase 1 study in Advanced CancersFirst studyNCT05380882 · 60 enrolled · China
  2. Jan 2, 2024Phase 2 study in Breast NeoplasmsNCT06202261 · 154 planned · China
  3. Jun 24, 2025Phase 3 study in HER2-positive Advanced Breast CancerNCT07047365 · 416 planned · China
  4. Mar 25, 2026Phase 2 study in Advanced Solid TumorNCT07512583 · 178 planned · China
  5. Jun 12, 2026Phase 2 study in Colorectal NeoplasmsNCT07653685 · 71 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Breast NeoplasmsNCT06202261
  2. Jun 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07653685
  3. Mar 2028Primary completion: phase 2 study in Advanced Solid TumorNCT07512583
  4. Jun 2028Primary completion: phase 3 study in HER2-positive Advanced Breast CancerNCT07047365

TargetBeta

“HER2双抗”the company's pipeline, read by Claude · source
“A bispecific antibody directed against two distinct domains of the tumor-associated antigen (TAA) human tyrosine kinase receptor epidermal growth factor receptor 2 (HER2; ErbB2; HER-2), ”NCIt, by rule

Other programs on ERBB2

ProgramCompanyFurthest phaseStudies
TrastuzumabruleHoffmann-La Rochephase 485
pertuzumabruleHoffmann-La Rochephase 456
trastuzumab deruxtecanruleDaiichi Sankyophase 449
tucatinibrulePfizerphase 425
disitamab vedotinRemeGenphase 336
trastuzumab rezetecanruleJiangsu HengRui Medicinephase 336
Lutetium-177Novartisphase 324
trastuzumab brengitecanSichuan Biokin Pharmaceuticalphase 321
Gallium-68Philogenphase 317
zongertinibruleBoehringer Ingelheimphase 315
Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102Sino Biopharmaceuticalphase 313
sunvozertinibruleDizal Pharmaceuticalsphase 312

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07653685Colorectal Neoplasms · China2RecruitingJun 202771
NCT07512583Advanced Solid Tumor · China2RecruitingMar 2028178
NCT07047365HER2-positive Advanced Breast Cancer · China3RecruitingJun 2028416
NCT06202261Breast Neoplasms · China2RecruitingDec 2026154
NCT05380882Advanced Cancers · China1UNKNOWNApr 202360

How it is read

Names in the registry

  • “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)+Bevacizumab injection”, 1 entry
  • “TQB2930 injection +(Oxaliplatin for injection + Capecitabine tablets)/( Irinotecan hydrochloride injection+ Capecitabine tablets)”, 1 entry
  • “TQB2930 injection+TQB2102 for injection”, 1 entry
  • “TQB2930+ chemotherapy”, 1 entry
  • “TQB2930 for injection”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.